People say these peptides hurt them. Their stories are muffled in MAHA’s push for medical freedom.

“There are millions of success stories with these peptides, but no one wants to believe that this wrecks some of our lives.”

By
Amy Maxmen
October 13, 2026
14 min

Kff Health News

Overview

The article describes people who report adverse effects after using BPC-157, an experimental peptide promoted online despite the absence of clinical trials establishing its safety or effectiveness. It also examines efforts by Make America Healthy Again (MAHA) leaders to expand access to experimental peptides, alongside regulatory uncertainty and limited human safety evidence.

Background

Peptides are substances made from the same building blocks as proteins, and some, including insulin and GLP-1 medicines, are FDA-approved. BPC-157 is not approved and has not undergone clinical trials, yet influencers have promoted it for a range of health and performance purposes. The article reports that use is growing in the United States and describes a preliminary analysis of electronic health records that identified more than 1,000 people who told doctors they had used BPC-157 since 2020. The FDA’s 2026 advisory materials, provided in the web research context, characterize available human safety data as limited.

Data Highlights

Evidence or event	Reported finding
U.S. use analysis	An unpublished analysis of millions of de-identified electronic health records found that more than 1,000 people had told doctors they used BPC-157 since 2020.
FDA advisory materials, 2026	FDA staff described BPC-157 as poorly characterized, with limited human safety data and immunogenicity concerns, particularly for subcutaneous and nasal routes.
Human exposure evidence summarized by FDA	Small, short-duration studies involved rectal, intra-articular, intravesical, and intravenous administration. The briefing reported no serious adverse events in those studies but said the evidence was insufficient to characterize safety.
Compounding advisory vote	On July 23, 2026, the advisory panel voted to recommend allowing compounding of BPC-157; the vote itself did not change the law, and FDA rulemaking would still be required.

Key Findings

Dylan Meetze reported fatigue, anxiety, and eye and muscle twitching after using intranasal BPC-157; he said the symptoms persisted for months after he stopped taking it.
The article says BPC-157 and other experimental peptides are promoted online for conditions and goals including muscle injuries, gut issues, COVID-19, and body optimization, despite a lack of clinical trial data establishing safety or effectiveness.
Meetze said he purchased BPC-157 from an online vendor whose website described its products as for laboratory research and not for human consumption.
The article reports that MAHA leaders, including Health Secretary Robert F. Kennedy Jr., have advocated making peptides more accessible, and that an FDA advisory panel voted to recommend easing restrictions on six experimental peptides, including BPC-157.
FDA briefing materials summarized in the web research context found limited human exposure data and no studies of BPC-157 administered by the oral, subcutaneous, nasal, or transdermal routes promoted online.
The FDA briefing summarized three adverse-event reports submitted to FAERS, including an injection-site reaction, shortness of breath requiring an emergency-room visit after subcutaneous injection, and diffuse hyperpigmentation with gingival darkening reported after co-administration with TB-500.

Clinical Implications

The source material does not establish BPC-157’s safety or effectiveness, and reported individual experiences do not determine causality. FDA briefing materials describe limited human safety data and note that the advisory panel’s compounding recommendation does not itself change the law or constitute FDA approval.

Conclusion

BPC-157 remains an experimental, unapproved substance promoted for human use despite limited clinical evidence. The article juxtaposes personal reports of harm with political efforts to expand access and continuing regulatory review.